IDF releases position statement recommending use of 1-hour plasma glucose test to diagnose intermediate hyperglycaemia and type 2 diabetes

The International Diabetes Federation (IDF) has released a Position Statement that presents the 1-hour post-load plasma glucose (1-h PG) test as a more sensitive and practical method to screen for intermediate hyperglycaemia (IH) and type 2 diabetes(T2D) in people at risk. The Statement was prepared by an international panel* of 22 experts from 15 countries and presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy and was published online in Diabetes Research and Clinical Practice. The Statement recommends the use of 1-h PG with the validated cut points of 155 mg/dL (8.6 mmol/L) for IH and 209 mg/dL (11.6 mmol/L) for T2D.

IH, sometimes referred to as “prediabetes,” is a state between normal glucose regulation (NGR) and T2D. It includes impaired fasting glycaemia (IFG) and impaired glucose tolerance (IGT). Many individuals with IH as defined by current diagnostic criteria, will progress to T2D. Evidence shows that T2D can be prevented by lifestyle modification and/or medications in people with IGT diagnosed by 2-h PG during a 75-gram oral glucose tolerance test (OGTT). Unfortunately, many people with T2D and those with IGT remain undiagnosed if an OGTT is not employed. Given the continued rising prevalence of diabetes worldwide, a more sensitive and practical method is therefore needed to detect people with IH and T2D for early diagnosis and intervention.

A wealth of epidemiological data has confirmed the superior value of 1-h PG over fasting PG (FPG), glycated haemoglobin (HbA1c) and 2-h PG in populations of different ethnicity, sex and age. The IDF Position Statement reviews findings that the 1-h post-load PG > 155 mg/dL (8.6 mmol/L) in those with NGR during an OGTT is highly predictive for detecting people at risk of progression to T2D, micro- and macrovascular complications, obstructive sleep apnoea, cystic fibrosis-related diabetes, metabolic dysfunction-associated steatotic liver disease, and premature death. Importantly, by using the 1-h PG cut points of 155 mg/dL (8.6 mmol/L) for diagnosing IH and 209 mg/dL (11.6 mmol/L) for diagnosing T2D, people at risk can be detected earlier than with the currently recommended glycaemic thresholds. Therefore, the IDF Position Statement recommends the adoption of 1-h PG with the aforementioned cut points.

The IDF Position Statement proposes the following pathway for detecting IH and T2D:

• People determined to be at high-risk for T2D through a validated screening tool (e.g. Finnish FINDRISC, ADA risk score) should undergo a 75-gram 1-h OGTT after an overnight fast.
• People with a 1-h PG value at or above 155 mg/dL (8.6 mmol/L) are considered to have IH and should be prescribed lifestyle intervention and referred to a diabetes prevention programme.
• People with a 1-h PG value at or above 209 mg/dL (11.6 mmol/L) are considered to have T2D. They should have a repeat test to confirm the diagnosis and then be referred for further evaluation and treatment.

Although there are challenges inherent in implementing the 1-h OGTT, using this test after screening with a non-laboratory diabetes risk tool will help identify people at high risk of T2D earlier and contribute to reducing the global impact of diabetes, advancing global public health beyond the significant achievements in diabetes prevention studies.

The expert panel was co-chaired by Professor Michael Bergman, Professor of Medicine and Population Health at New York University Grossman School of Medicine, New York City and Professor Jaakko Tuomilehto, Professor Emeritus of Public Health, University of Helsinki, Finland, and Visiting Scientist, Finnish Institute for Health and Welfare, Helsinki, Finland. Leadership and support for this initiative were provided by Professor Akhtar Hussain, President of the International Diabetes Federation, Professor (Diabetes & Metabolic Disorder) NORD University, Bodø, Norway and Professor Antonio Ceriello IRCCS MultiMedica, Milan, Italy.

Access the statement here.